Patients Continue To Risk Blindness As Nice Recommends Only Single Therapy In Latest Amd Guidance

Pfizer Limited expresses concern that the latest NICE appraisal consultation document (ACD) regarding the use of treatments for wet Age-related Macular Degeneration (AMD), fails to provide any treatment choice for patients or physicians, by recommending only one anti-VEGF therapy for AMD. [click link for full article]

More: continued here

Filed under: Eye Health on December 20th, 2007